Last updated: May 23, 2026
Executive summary: Public clinical-trial and commercial-market reporting for technetium Tc-99m mebrofenin is sparse compared with higher-profile radiopharmaceuticals. The asset’s value is driven primarily by regulatory supply of diagnostic imaging kits, generator-derived Tc-99m availability, and facility throughput rather than large-scale late-stage trials. Without a clearly identifiable current Phase 3 or pivotal Phase 2 program in the public domain, the most decision-relevant forward view is a “capacity and access” forecast: expected demand tracks nuclear medicine procedure volumes, hospital imaging adoption, payer mix for hepatobiliary indications, and vendor supply continuity. Market upside is constrained by (1) radiopharmacy manufacturing and distribution bottlenecks, (2) lead times tied to Mo-99/Tc-99m generator economics, and (3) competition from other hepatobiliary tracers used for cholescintigraphy and biliary obstruction workflows.
What is technetium Tc-99m mebrofenin used for and what does its clinical evidence focus on?
Technetium Tc-99m mebrofenin is a radiopharmaceutical used for hepatobiliary scintigraphy, most commonly to support evaluation of biliary patency, gallbladder function, and biliary obstruction patterns (cholescintigraphy workflows). The clinical evidence base for this class typically relies on diagnostic performance endpoints (visualization rates, time-activity curves, sensitivity/specificity against reference standards) rather than disease-modifying outcomes.
What endpoints define clinical success for mebrofenin in hepatobiliary imaging?
Common endpoint categories in hepatobiliary radiotracer studies include:
- Gallbladder visualization rate after standardized dosing and imaging time windows
- Hepatic uptake and biliary excretion kinetics (quantitative time-activity parameters)
- Diagnostic agreement with reference diagnostics such as ultrasound, CT, MRCP, ERCP, operative findings, or clinical course
What patient groups are typically studied?
Studies for hepatobiliary tracers usually include:
- Adults with suspected acute cholecystitis and biliary obstruction
- Patients requiring evaluation of biliary dyskinesia or post-operative biliary complications
- Pediatric cohorts in settings where diagnostic imaging is needed and radiation safety constraints are managed
Does mebrofenin have a defined competitive clinical “niche”?
The niche is imaging reliability under standard protocols and logistical practicality for nuclear medicine departments, where workflow and tracer performance under routine conditions matter.
What is the current clinical trials update for technetium Tc-99m mebrofenin?
A reliable “current trial update” requires an up-to-date registry view (e.g., ClinicalTrials.gov) showing active studies, phases, enrollment status, and completion dates. Publicly accessible updates for technetium Tc-99m mebrofenin are not consistently available in a way that supports a complete, date-stamped status summary without risking factual inaccuracies.
What types of trials are most likely to appear for Tc-99m hepatobiliary tracers?
When new studies are run for Tc-99m imaging agents, they tend to be:
- Comparative imaging studies versus alternative hepatobiliary tracers
- Protocol optimization studies (dose, imaging intervals, collimator settings, quantitative methods)
- Label-expansion studies for specific populations or clinical indications
- Manufacturing/quality bridging studies, which may not be labeled “clinical efficacy” trials
How to interpret “clinical trials update” for radiopharmaceuticals versus drugs?
Radiopharmaceutical development often proceeds through:
- Regulatory chemistry and manufacturing controls
- Stability, biodistribution, and diagnostic performance bridging
- Validation of labeling and imaging protocol rather than large outcome trials
What is the Orange Book status of technetium Tc-99m mebrofenin and what does that imply for exclusivity?
Technetium Tc-99m mebrofenin is a diagnostic radiopharmaceutical. The US regulatory IP landscape for Tc-99m products is typically reflected in FDA listings and patents rather than the standard small-molecule drug model. A definitive Orange Book status analysis requires specific FDA listing entries for the product and associated patent numbers and exclusivity codes.
Key question: does Orange Book list any patents or exclusivity for this tracer?
For a complete answer, the FDA Orange Book record for the specific product name, NDA/BLA number, and dosage form is required, including:
- Patent numbers tied to the NDA
- Expiration dates and listed claims
- Exclusivity blocks and periods (if any)
Because that information is not provided here as specific FDA listing data, a complete status map cannot be produced.
When does technetium Tc-99m mebrofenin lose exclusivity and when could generics enter?
Loss of exclusivity and generic entry depends on:
- NDA exclusivity (if applicable)
- Patent expiration for composition-of-matter, method-of-use, formulation, or manufacturing process claims
- 505(b)(2) pathway use by competitors
- Radiopharmaceutical-specific supply authorization and labeling
A date-accurate exclusivity timeline cannot be constructed without the underlying FDA listing and patent expiration dataset.
How many patents cover technetium Tc-99m mebrofenin and what are the likely claim types?
Radiopharmaceutical IP typically includes:
- Kit composition and formulation claims (e.g., lyophilized kit components)
- Radiolabeling method claims (how Tc-99m is incorporated)
- Stability and shelf-life claims
- Use claims tied to imaging procedures or diagnostic protocols
A quantified patent count with numbers, assignees, and jurisdictions requires an identified patent estate. Without that, the analysis would be incomplete.
What generic entry risks exist for technetium Tc-99m mebrofenin?
Generic risk for Tc-99m imaging kits is shaped by:
- Formulation replicability and radiochemical purity requirements
- Validation of labeling-imaging workflow performance
- Manufacturing controls and distribution cold-chain logistics
- Regulatory filing pathway and any bridging study obligations
Where risk concentrates
- Quality equivalence and on-site performance consistency at nuclear medicine facilities
- Batch release and radiochemical stability during distribution
- Labeling acceptance for standardized imaging times and interpretation protocols
Which companies sell technetium Tc-99m mebrofenin and how does the competitive landscape look?
The competitive landscape for technetium Tc-99m mebrofenin generally includes:
- Branded kit manufacturers supplying nuclear medicine departments
- Radiopharmacy suppliers and distributors in regional markets
- Alternative hepatobiliary Tc-99m tracers, depending on local formularies and reimbursement
A precise market-share ranking, company list, and installed-base view requires product-level sales data by manufacturer and national tender history, which is not available in the prompt.
What is the market size for technetium Tc-99m mebrofenin and what growth drivers should investors track?
For radiopharmaceuticals used for imaging, market value tends to be a function of procedure volumes and reimbursement intensity rather than patient prevalence. Forecasting should track:
- Annual volume of hepatobiliary scans (including suspected acute cholecystitis workflows)
- Conversion of imaging utilization from ER/urgent pathways into routine imaging schedules
- Reimbursement trends in the US and major EU markets
- Nuclear medicine department capacity, scanner throughput, and scheduling intensity
- Mo-99/Tc-99m generator supply stability, which affects availability and substitute utilization
Demand sensitivity to supply continuity
Radiopharmaceuticals are supply-constrained when generator availability tightens. When Tc-99m supply is scarce, departments sometimes switch imaging protocols or defer scans, reducing tracer demand. When supply is stable, demand increases with scheduling.
How should you project technetium Tc-99m mebrofenin revenue over the next 5–10 years?
A practical forecast framework for Tc-99m mebrofenin uses:
- Procedure volume forecast (hepatobiliary scintigraphy volume growth or stagnation)
- Net price forecast (tender-driven declines, payer negotiations, product-specific mix)
- Market share dynamics (share shifts among Tc-99m hepatobiliary tracers and competing imaging agents)
- Supply constraints (generator-related disruptions and allocation effects)
- Regulatory/label changes that shift imaging indications
Base-case projection logic (directional)
- If hepatobiliary scan volumes grow modestly with imaging adoption, revenues should track low-single-digit volume growth, tempered by price pressure from sourcing competition.
- If supply disruptions occur, revenues may show volatility due to allocation and deferred imaging.
- Structural growth depends more on hospital throughput and reimbursement than on new clinical evidence.
Because numeric inputs (current revenues, unit sales, pricing, procedure volumes, and competitor pricing) are not provided, a numerical forecast would risk fabrication.
How does technetium Tc-99m mebrofenin compare with competing hepatobiliary tracers in market access and clinical workflows?
In hepatobiliary imaging, competitive positioning is determined by:
- Diagnostic performance under standardized protocols
- Time to visualization and interpretability
- Labeling breadth and acceptance in institutional imaging pathways
- Supply reliability for routine scheduling
Comparison axes that matter to procurement
- Turnaround time for radiopharmacy ordering and delivery
- Kit stability and radiochemical quality under distribution conditions
- Evidence and protocol compatibility with existing nuclear medicine SOPs
- Tender pricing and contract reliability
What FDA regulatory milestones affect technetium Tc-99m mebrofenin availability?
Regulatory milestones affecting radiopharmaceutical availability typically include:
- NDA/ANDA or 505(b)(2) approval or supplement approvals
- Changes in manufacturing site authorization (CMC supplements)
- Label updates for dosing, indications, and imaging protocols
- Safety updates related to radiation exposure guidance
A milestone table requires specific FDA submission and approval dates for the marketed product.
What patent litigation affects technetium Tc-99m mebrofenin and biosimilar-like risk?
There is no biosimilar risk for Tc-99m small radiotracers in the biologics sense. Litigation risk, if present, would arise from:
- Patent disputes tied to kit formulation or method-of-use claims
- 505(b)(2) or ANDA-related challenges by competitors
- Injunctions affecting supply and market entry
A litigation-impact analysis requires identified cases and dockets tied to the product’s patent estate.
Key Takeaways
- Technetium Tc-99m mebrofenin is used for hepatobiliary scintigraphy and its clinical value concentrates on diagnostic imaging performance and workflow reliability.
- Public, date-stamped “current clinical trials” details are not sufficiently available in the prompt to support a complete Phase-by-Phase update.
- The market forecast for Tc-99m radiopharmaceuticals is driven mainly by procedure volume trends, net pricing and tendering, and Tc-99m supply continuity rather than blockbuster-like exclusivity dynamics.
- A decision-grade exclusivity, patent, and litigation timeline cannot be produced without product-specific FDA listing and patent data.
FAQs
1) What imaging indications are most commonly billed for technetium Tc-99m mebrofenin in hepatobiliary scintigraphy?
2) How does Tc-99m generator supply disruption affect utilization and substitution patterns for hepatobiliary scans?
3) What labeling and imaging-protocol elements most influence hospital adoption of Tc-99m mebrofenin kits?
4) What regulatory pathway do competitors typically use for Tc-99m diagnostic kits in the US (505(b)(2) versus ANDA) and what studies are required?
5) How do tender contracts and group purchasing affect net pricing for radiopharmaceutical kits like technetium Tc-99m mebrofenin?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. (Accessed: 2026-05-23).
- ClinicalTrials.gov. US National Library of Medicine. (Accessed: 2026-05-23).
- FDA. Guidance for Industry: Radiopharmaceuticals for Diagnostic Use. US Food and Drug Administration. (Referenced conceptually).
